• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Global Wellness Institute Announces New Psychedelics Initiative

Microdose by Microdose
March 15, 2022
in Industry
Reading Time: 9 mins read
A A
Global Wellness Institute Announces New Psychedelics Initiative

The Initiative will support collaboration and coalition building, and ethics and best practices, in the psychedelic community.

High-profile lineup of members includes Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS)

See the full press release below

 

 

Miami, FL – March 15, 2022 – The nonprofit Global Wellness Institute™ (GWI), the leading research and educational resource for the $4.4 trillion global wellness industry, welcomes a new Initiative: The Psychedelics & Healing Initiative. The launch of this project, which joins the GWI’s portfolio of 33 collaborative initiatives, comes at a time when the FDA has granted some psychedelics “breakthrough” status as new mental health treatments.

Researchers around the globe—–and at some of America’s most distinguished medical institutions—–are looking closely at how psychedelic medicines could provide treatment for intractable medical issues such as depression, anxiety, alcoholism, substance abuse and post-traumatic stress disorder (PTSD). The clinical evidence increasingly indicates that psychedelics can make a difference. 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Policy changes throughout the United States are changing the regulatory landscape. Wall Street is part of the new geography too: Psychedelic pharmaceutical companies are now publicly listed on the New York Stock Exchange, the NASDAQ, and the Canadian Securities Exchange. 

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

As the world awakens to the benefits of psychedelics, among the challenges ahead are how the psychedelic community will forge a unified and thoughtful voice to help identify and address emerging issues. The GWI’s Chair and CEO, Susie Ellis, welcomed the new initiative as a wellness industry first: “Psychedelic healing has arrived. As this movement grows and receives regulatory approvals, an Initiative that brings together respected leaders to focus on evidence-based best practices, equity and accessibility, is very much needed if we want to realize the potential for psychedelics in helping address the global mental health crisis.”

Rick Doblin, PhD, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), will serve as the Initiative’s Honorary Chair. Dr. Doblin’s keynote remarks at the 2021 Global Wellness Summit outlined a future for wellness where psychedelic-based medicine would take its place among long-established preventative and self-care approaches, such as meditation and stress-management. A video of his historic keynote, the first from a psychedelic advocate and researcher to the wellness industry, is available on the Global Wellness Summit website.

Who: The GWI’s Psychedelics & Healing Initiative is a collaboration between leading physicians, business innovators, research scientists, impact investors, and policymakers from psychedelic organizations that exemplify the highest ideals of healing and community-building. Many are actively engaged in advocacy and the exploration of how psychedelics can heal, expand consciousness and nurture community.

The founding m

Buy Lasix – Special Offer

embers of the Initiative are:

Rick Doblin, PhD, is Honorary Chair of the Initiative and founder and executive director, Multidisciplinary Association for Psychedelic Studies (MAPS)

Mary-Elizabeth Gifford, EVP, Psyence Group

Paul Hutson, PhD, professor and founding director, Transdisciplinary Center for Research in Psychoactive Substances at the University of Wisconsin, Madison

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Melissa Lavasani, founder and executive director, Psychedelic Medicine Coalition

Lynn Marie Morski, MD, JD, president, Psychedelic Medicine Association 

Louie Schwartzberg, filmmaker; director of Fantastic Fungi; founder of Visual Healing for Wellness

Sa’ad Shah, co-founder, Noetic Fund

Dingle Spence, MD, co-founder, Jamaica Cancer Care & Research Institute; Board of Directors, International Association for Hospice and Palliative Care; and Advisory Board member, the EndWell Project

Kathryn Tucker, JD, co-founder, Psychedelic Bar Association; Special Counsel, Emerge Law Group

Hanifa Nayo Washington, co-founder and chief of strategy, Fireside Project

What: Ethics, safety and best practices are among this new Initiative’s priorities—–as are equity, access and reciprocity. The Psychedelics & Healing Initiative will offer support to those in the field already generating resources for ethics and standards for psychedelic medicines and provide an online home with links to a virtual “wisdom well” of best practices. Policy updates, continuing education, and regional outreach are also planned. On an international level, the Initiative will work in support of the recently launched International Therapeutic Rescheduling Initiative, ITPRI, a Swiss-based movement to reform the United Nation’s pharmaceutical treaties. 

Learn more about its mission and founding members here.

About the Global Wellness Institute: The Global Wellness Institute (GWI), a nonprofit 501(c)(3), is considered the leading global research and educational resource for the global wellness industry and is known for introducing major industry initiatives that bring together leaders to chart the future. GWI positively impacts global health and wellness by educating public institutions, businesses and individuals on how they can work to prevent disease, reduce stress and enhance the overall quality of life. Its mission is to empower wellness worldwide.

Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post
Is the UK Becoming a Global Center for Psychedelic Medicine?

Is the UK Becoming a Global Center for Psychedelic Medicine?

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.